Effects of Artificial Sweetener on Gastrointestinal (GI) Peptide Secretion
NCT ID: NCT00978900
Last Updated: 2009-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
12 participants
INTERVENTIONAL
2008-12-31
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Different Concentrations of Xylitol and Erythritol on Gut Peptide Release and Gastric Emptying in Humans
NCT03039478
Metabolic Effects of Non-Nutritive Sweeteners
NCT01200940
Acute Effects of the Two Alternative Sweeteners D-allulose and Erythritol on Metabolism
NCT04027283
The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adults
NCT02335021
The Influence of Sweet Substrates on Hunger, Gastrointestinal Hormones and the Migrating Motor Complex
NCT02891525
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acesulfame K
Artificial sweeteners; Carbohydrate Sugars
sweetening agent dissolved in tap water, administered via intragastric tube
Sucralose
Artificial sweeteners; Carbohydrate Sugars
sweetening agent dissolved in tap water, administered via intragastric tube
Aspartame
Artificial sweeteners; Carbohydrate Sugars
sweetening agent dissolved in tap water, administered via intragastric tube
Glucose
Artificial sweeteners; Carbohydrate Sugars
sweetening agent dissolved in tap water, administered via intragastric tube
Fructose
Artificial sweeteners; Carbohydrate Sugars
sweetening agent dissolved in tap water, administered via intragastric tube
Water
Water
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Artificial sweeteners; Carbohydrate Sugars
sweetening agent dissolved in tap water, administered via intragastric tube
Water
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal eating habits
* Age 18-40 years
* Stable body weight for at least three months
Exclusion Criteria
* Substance abuse
* Regular intake of medications (except for oral contraceptives)
* Medical or psychiatric illness
* history of gastrointestinal disorders
* food allergies
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Basel, Switzerland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department of Gastroenterology, University Hospital, Basel, Switzerland
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christoph Beglinger, MD
Role: PRINCIPAL_INVESTIGATOR
Clinical Research Center, University Hospital Basel
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EKBB 69/04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.